Overview

Location [1]
11q13.5
Pathways
DNA damage/repair, Cell cycle control
Synonyms [1]
GL002, EMSY

C11orf30 is altered in 2.67% of all cancers with non-small cell lung carcinoma, colorectal adenocarcinoma, melanoma, breast carcinoma, and bladder carcinoma having the greatest prevalence of alterations [3].

C11orf30 GENIE Cases - Top Diseases

The most common alterations in C11orf30 are C11orf30 Mutation (0.16%), C11orf30 P958L (0.01%), C11orf30 R744S (0.01%), C11orf30 I494V (0.00%), and C11orf30 R744H (0.00%) [3].

C11orf30 GENIE Cases - Top Alterations

Significance of C11orf30 in Diseases

Malignant Solid Tumor +

Prostate Adenocarcinoma +

Prostate Carcinoma +

Breast Carcinoma +

Ovarian Carcinoma +

Colorectal Carcinoma +

Non-Hodgkin Lymphoma +

Cervical Carcinoma +

Small Cell Lung Carcinoma +

Cholangiocarcinoma +

Adenocarcinoma Of The Gastroesophageal Junction +

Gastric Carcinoma +

Lung Adenocarcinoma +

Non-Small Cell Lung Carcinoma +

Urothelial Carcinoma +

Pancreatic Carcinoma +

Pancreatic Adenocarcinoma +

High Grade Ovarian Serous Adenocarcinoma +

Anal Carcinoma +

Cancer +

Clear Cell Renal Cell Carcinoma +

Diffuse Large B-Cell Lymphoma +

Endometrial Carcinoma +

Fallopian Tube Carcinoma +

Head And Neck Squamous Cell Carcinoma +

Histiocytic And Dendritic Cell Neoplasm +

Mantle Cell Lymphoma +

Mature T-Cell And NK-Cell Non-Hodgkin Lymphoma +

Mesothelioma +

Penile Carcinoma +

Peritoneal Carcinoma +

Soft Tissue Sarcoma +

Squamous Cell Lung Carcinoma +

Uveal Melanoma +

Vaginal Carcinoma +

Vulvar Carcinoma +

References

1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20170629. San Francisco CA: Github;2015. https://github.com/biocommons/uta

2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.

3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 4. This dataset does not represent the totality of the genetic landscape; see paper for more information.

4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.